Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Tislelizumab + Chemotherapy in Advanced Gastric Cancer
NCT06238752Phase 2Completed
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric adenocarcinoma, sponsored by Renmin Hospital of Wuhan University. Primary endpoint: Progression-Free Survival at 1 year. Started Mar 2021; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT06238752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238752.